SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Abstract oriental Japanese art vector background in red color, traditional style design, wavy shapes and mountains terrain landscape, runny like sea lines.
Duchenne muscular dystrophy
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
March 26, 2025
 · 
3 min read
 · 
Heather McKenzie
Interest rate and tax concept. A percentage symbol and arrow symbol on wooden cube. Interest rates continue to increase, return on stocks and mutual. funds, finance, growth, increase, profit. FED.
Government
Tariffs Would Impede Access to Affordable Drugs, Industry Warns
Donald Trump’s proposed tariffs on the EU would increase manufacturing costs for pharma companies and would stall medical innovation, according to the results of a recent survey by the Biotechnology Innovation Organization.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Paper human heads with colorful puzzle pieces on a light background. World autism day concept
Alzheimer’s disease
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
A doctor's hand in a blue medical glove holding a jar of medicine or vitamins on a blue background with copy space. Vector illustration in flat style
FDA
GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in the second half of this year.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Government
Senate Confirms Makary as FDA Chief as Trump’s Health Nominees Move Forward
Marty Makary earlier this month distanced himself from the recent shake-ups at the FDA, including the cancellation of its vaccines advisory committee meeting and the steep layoffs at the agency.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
 · 
1 min read
 · 
Heather McKenzie
A look into the future. Concept. stock photo
GLP-1
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the territory covered and what’s to come.
March 26, 2025
 · 
2 min read
 · 
Annalee Armstrong
Contemporary art collage. Person climbs a pile of colorful capsules, symbolizing struggle and progress in surreal pharmaceutical world. Flag marks goal at top. stock photo
Manufacturing
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.
March 26, 2025
 · 
6 min read
 · 
Ben Hargreaves
Receiving dividends among investors. Art collage.
Biosimilars
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market.
March 26, 2025
 · 
6 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS